Eikon Therapeutics, Inc. (EIKN) Income Statement
EIKN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsEIKN revenue and net income
EIKN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
EIKN quarterly EPS vs estimates
Eikon Therapeutics beat the analyst EPS estimate in 0 of the last 3 quarters. Next report: November 12, 2026 (estimate $-1.74).
EIKN income statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of revenue | $24.2M | — | — |
| Gross profit | −$24.2M | — | — |
| Research & development | $250.3M | $204.5M | $207.3M |
| Sales, general & admin | $88.6M | $55.8M | $58.5M |
| Total operating expenses | $314.8M | $260.3M | $265.7M |
| Operating income | −$338.9M | −$260.3M | −$265.7M |
| Interest income | $15.6M | $16.6M | $23.7M |
| Interest expense | $837,000 | $31,000 | $39,000 |
| Income before taxes | −$324.2M | −$243.8M | −$242.0M |
| Net income | −$324.2M | −$243.8M | −$242.0M |
| EBITDA | −$299.2M | −$218.4M | −$224.2M |
| EPS (diluted) | −$26.23 | −$4.52 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $5.0M | $5.1M | $5.1M | — | — | — | — |
| Gross profit | −$5.0M | −$5.1M | −$5.1M | — | — | — | — |
| Research & development | $75.5M | $70.0M | $65.2M | $59.3M | $69.2M | $56.6M | $53.9M |
| Sales, general & admin | $17.9M | $17.3M | $17.9M | $15.4M | $40.5M | $14.8M | $13.9M |
| Total operating expenses | $88.4M | $82.2M | $78.1M | $74.8M | $109.6M | $71.4M | $67.8M |
| Operating income | −$93.4M | −$87.3M | −$83.2M | −$74.8M | −$109.6M | −$71.4M | −$67.8M |
| Interest income | — | $4.4M | $3.5M | — | — | $3.2M | $2.9M |
| Interest expense | — | — | $48,000 | — | — | — | $7,000 |
| Income before taxes | −$88.4M | −$83.0M | −$79.7M | −$71.1M | −$105.2M | −$68.2M | −$64.9M |
| Net income | −$88.4M | −$83.0M | −$79.7M | −$71.1M | −$105.2M | −$68.2M | −$64.9M |
| EBITDA | −$88.4M | −$77.8M | −$74.5M | −$56.4M | −$103.3M | — | — |
| EPS (diluted) | −$1.63 | −$2.46 | −$26.23 | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in EIKN's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
EIKN financial results
Eikon Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $324.2 million. Diluted earnings per share came to −$26.23.
See the EIKN stock overview for the latest quote and news, or the EIKN chart for price history and technical indicators.
EIKN income statement FAQ
Does Eikon Therapeutics have revenue?
Eikon Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Eikon Therapeutics profitable?
No. Eikon Therapeutics reported a net loss of $324.2 million in fiscal 2025.
How much does Eikon Therapeutics spend on research and development?
Eikon Therapeutics spent $250.3 million on research and development in fiscal 2025.
What are Eikon Therapeutics's earnings per share?
Eikon Therapeutics earned $-26.23 per diluted share in fiscal 2025, compared with $-4.52 a year earlier.
When will Eikon Therapeutics report its next earnings?
Eikon Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes.
When does Eikon Therapeutics's fiscal year end?
Eikon Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.